{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:34:30Z","timestamp":1762209270553,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Key Technologies R&D Program of Guangdong Province","award":["2023B1111030004"],"award-info":[{"award-number":["2023B1111030004"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373938","82204585"],"award-info":[{"award-number":["82373938","82204585"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFF1202600"],"award-info":[{"award-number":["2022YFF1202600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jpet.2025.103623","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T18:54:48Z","timestamp":1749236088000},"page":"103623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Absorption, distribution, metabolism, and excretion of [14C]SHEN211, a nonpeptidic small-molecule 3CLpro inhibitor, in rats"],"prefix":"10.1016","volume":"392","author":[{"given":"Zihao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengting","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanhuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yali","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoran","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congmei","family":"Ming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaokun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuandong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingxing","family":"Diao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2025.103623_bib1","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3390\/v16060844","article-title":"3-Chymotrypsin-like protease (3CLpro) of SARS-CoV-2: validation as a molecular target, proposal of a novel catalytic mechanism, and inhibitors in preclinical and clinical trials","volume":"16","author":"Amorim","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.jpet.2025.103623_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.134642","article-title":"Glycyrrhizin as a promising kryptonite against SARS-CoV-2: clinical, experimental, and theoretical evidences","volume":"1275","author":"Banerjee","year":"2023","journal-title":"J Mol Struct"},{"key":"10.1016\/j.jpet.2025.103623_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e40404","article-title":"Exploring the key structural attributes and chemico-biological interactions of pyridinone-based SARS-CoV-2 3CLpro inhibitors through validated structure-based drug design strategies","volume":"10","author":"Banerjee","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.jpet.2025.103623_bib4","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jpet.2025.103623_bib5","first-page":"162","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jpet.2025.103623_bib6","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41573-023-00703-8","article-title":"Deuterium in drug discovery: progress, opportunities and challenges","volume":"22","author":"Di Martino","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jpet.2025.103623_bib7","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2174\/1389200224666230705142901","article-title":"Pharmacokinetics, mass balance, tissue distribution, and metabolism of [3H]catalpol in rats: the main bioactive component of Rehmannia glutinosa for the treatment of ischemic stroke","volume":"24","author":"Ge","year":"2023","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.jpet.2025.103623_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104502","article-title":"From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses","volume":"85","author":"Kirtipal","year":"2020","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.jpet.2025.103623_bib9","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1021\/acs.jmedchem.7b01664","article-title":"Design and synthesis of novel deuterated ligands functionally selective for the \u03b3-aminobutyric acid type A receptor (GABAAR) \u03b16 subtype with improved metabolic stability and enhanced bioavailability","volume":"61","author":"Knutson","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpet.2025.103623_bib10","doi-asserted-by":"crossref","DOI":"10.2144\/fsoa-2023-0020","article-title":"Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease","volume":"9","author":"Kuang","year":"2023","journal-title":"Future Sci OA"},{"key":"10.1016\/j.jpet.2025.103623_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112711","article-title":"The development of coronavirus 3C-like protease (3CLpro) inhibitors from 2010 to 2020","volume":"206","author":"Liu","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jpet.2025.103623_bib12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1208\/s12248-020-00532-2","article-title":"Recent developments on therapeutic and diagnostic approaches for COVID-19","volume":"23","author":"Majumder","year":"2021","journal-title":"AAPS J"},{"key":"10.1016\/j.jpet.2025.103623_bib14","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1021\/acs.jmedchem.8b01808","article-title":"Applications of deuterium in medicinal chemistry","volume":"62","author":"Pirali","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpet.2025.103623_bib15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jpha.2021.03.012","article-title":"Reducing SARS-CoV-2 pathological protein activity with small molecules","volume":"11","author":"Pluskota-Karwatka","year":"2021","journal-title":"J Pharm Anal"},{"key":"10.1016\/j.jpet.2025.103623_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109721","article-title":"Drugs targeting various stages of the SARS-CoV-2 life cycle: exploring promising drugs for the treatment of Covid-19","volume":"74","author":"Poduri","year":"2020","journal-title":"Cell Signal"},{"key":"10.1016\/j.jpet.2025.103623_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12998\/wjcc.v10.i1.1","article-title":"Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance","volume":"10","author":"Ren","year":"2022","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.jpet.2025.103623_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173926","article-title":"Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis","volume":"897","author":"Rezagholizadeh","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpet.2025.103623_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/1060028018797110","article-title":"Impact of deuterium substitution on the pharmacokinetics of pharmaceuticals","volume":"53","author":"Russak","year":"2019","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jpet.2025.103623_bib20","first-page":"295","article-title":"Enhanced plasma concentration by selective deuteration of rofecoxib in rats","volume":"56","author":"Schneider","year":"2006","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.jpet.2025.103623_bib21","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.cmi.2022.04.015","article-title":"First-generation oral antivirals against SARS-CoV-2","volume":"28","author":"Sendi","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jpet.2025.103623_bib22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1358\/dnp.2010.23.6.1426638","article-title":"The kinetic isotope effect in the search for deuterated drugs","volume":"23","author":"Shao","year":"2010","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.jpet.2025.103623_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00632-22","article-title":"Safety, tolerability, and pharmacokinetics of the novel antiviral agent ensitrelvir fumaric acid, a SARS-CoV-2 3CL protease inhibitor, in healthy adults","volume":"66","author":"Shimizu","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jpet.2025.103623_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmbts.2023.09.001","article-title":"SARS-CoV-2-Virus structure and life cycle","volume":"202","author":"Tebha","year":"2024","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.jpet.2025.103623_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127377","article-title":"The SARS-CoV-2 main protease as drug target","volume":"30","author":"Ullrich","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jpet.2025.103623_bib26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V'Kovski","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jpet.2025.103623_bib27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/em.22471","article-title":"Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir","volume":"63","author":"Waters","year":"2022","journal-title":"Environ Mol Mutagen"},{"key":"10.1016\/j.jpet.2025.103623_bib28","doi-asserted-by":"crossref","DOI":"10.1080\/16549716.2024.2345968","article-title":"China\u2019s policies: post-COVID-19 challenges for the older population","volume":"17","author":"Wei","year":"2024","journal-title":"Glob Health Action"},{"key":"10.1016\/j.jpet.2025.103623_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115279","article-title":"An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: promises and challenges","volume":"205","author":"Xu","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jpet.2025.103623_bib31","doi-asserted-by":"crossref","first-page":"8102","DOI":"10.3390\/molecules28248102","article-title":"Absorption, distribution, metabolism, and excretion of [14C]BS1801, a selenium-containing drug candidate, in rats","volume":"28","author":"Yang","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.jpet.2025.103623_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105586","article-title":"Synthesis of deuterated S-217622 (ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2","volume":"213","author":"Yang","year":"2023","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jpet.2025.103623_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116012","article-title":"Absorption, distribution, metabolism and excretion of linaprazan glurate in rats","volume":"242","author":"Zhang","year":"2024","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.jpet.2025.103623_bib34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2147\/DDDT.S359009","article-title":"Progress on SARS-CoV-2 3CLpro inhibitors: inspiration from SARS-CoV 3CLpro peptidomimetics and small-molecule anti-inflammatory compounds","volume":"16","author":"Zhu","year":"2022","journal-title":"Drug Des Devel Ther"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:31:46Z","timestamp":1762209106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525398368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0022356525398368"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103623","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Absorption, distribution, metabolism, and excretion of [14C]SHEN211, a nonpeptidic small-molecule 3CLpro inhibitor, in rats","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103623","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103623"}}